The immunotoxin gemetuzumab ozogamicin (OG, Mylotarg; Wyeth, Madison, NJ, USA), which consists of a humanized anti-CD33 (siglec-3) murine antibody linked to calicheamicin, was approved by the FDA for treatment of CD33+ AML patients. This evidence concerns the gene CD33 and acute myeloid leukemia.